Genomics of medulloblastoma: from Giemsa-banding to next-generation sequencing in 20 years

PAUL A. NORTHCOTT, M.Sc.,¹⁻³ JAMES T. RUTKA, M.D., Ph.D.,^{1,3}
AND MICHAEL D. TAYLOR, M.D., Ph.D.¹⁻³

¹*Division of Neurosurgery, Arthur and Sonia Labatt Brain Tumour Research Centre;*

²*Program in Developmental and Stem Cell Biology, The Hospital for Sick Children;*

and ³*Department of Laboratory Medicine and Pathobiology, University of Toronto, Ontario, Canada*

Advances in the field of genomics have recently enabled the unprecedented characterization of the cancer genome, providing novel insight into the molecular mechanisms underlying malignancies in humans. The application of high-resolution microarray platforms to the study of medulloblastoma has revealed new oncogenes and tumor suppressors and has implicated changes in DNA copy number, gene expression, and methylation state in its etiology. Additionally, the integration of medulloblastoma genomics with patient clinical data has confirmed molecular markers of prognostic significance and highlighted the potential utility of molecular disease stratification. The advent of next-generation sequencing technologies promises to greatly transform our understanding of medulloblastoma pathogenesis in the next few years, permitting comprehensive analyses of all aspects of the genome and increasing the likelihood that genomic medicine will become part of the routine diagnosis and treatment of medulloblastoma. (DOI: 10.3171/2009.10.FOCUS09218)

KEY WORDS • medulloblastoma • genomics • microarrays • next-generation sequencing

GENOMICS involves the study of genes and their function, typically in the context of an organism, a tissue, or a particular cell type. Cancer is a genomic disease that accounted for an estimated ~ 640,000 deaths in the US and Canada in 2008.^{73,97} The goal of cancer genomics is to develop a comprehensive inventory of the full spectrum of mutations, whether inherited or acquired, that contribute to tumorigenesis. Ultimately, through a better understanding of the cancer genome, targeted treatment options can be developed and implemented so that deaths due to cancer can be reduced in the future.

The human genome consists of ~ 3 billion base pairs of DNA and encodes an estimated ~ 24–25,000 unique protein-coding genes.^{71,133} During tumorigenesis, a vari-

ety of somatic mutations arise at the level of the genome, collectively providing a selective growth advantage to cells harboring these mutations and promoting the onset of cancer. Some examples of the somatic mutations in the cancer genome include single base pair substitutions, insertions and deletions of DNA segments, structural rearrangements such as duplications, inversions, and translocations, as well as gene amplifications and deletions.¹⁴⁹ Estimates from recent genome-wide sequencing efforts have suggested that a given cancer may contain anywhere from 40 to over 100 somatic mutations.^{78,125,173} Since these numbers do not directly account for genes affected by structural changes and copy number aberrations, the actual number of genes targeted for mutation in a given tumor is probably even higher. Beyond the genome, deregulation of the epigenome, including hypermethylation of gene promoters and changes to the histone code, also contributes to cellular transformation.^{23,75,76,156} Collectively, these abnormal genomic and epigenomic states in a cancer cell aberrantly impact gene expression, leading to the disruption of normal cellular processes, including cell division. Comprehensive cancer genomics, therefore, include studies at the level of the genome, epigenome, and transcriptome.

Medulloblastoma is an embryonal tumor of the cerebellum and the most common malignant brain tumor

Abbreviations used in this paper: aCGH = array comparative genomic hybridization; CGNP = cerebellar granule neuron precursor; FISH = fluorescence in situ hybridization; G-banding = Giemsa banding; MAPK = mitogen-activated protein kinase; miRNA = microRNA; NGS = next-generation sequencing; PDGFR = platelet-derived growth factor receptor; RT-PCR = reverse transcriptase–polymerase chain reaction; SAGE = serial analysis of gene expression; SHH = sonic hedgehog; siRNA = short interfering RNA; SKY = spectral karyotyping; SNP = single-nucleotide polymorphism; sPNET = supratentorial primitive neuroectodermal tumor; TCGA = The Cancer Genome Atlas; TMA = tissue microarray; 5-aza = 5-aza-2'-deoxycytidine.

in childhood.^{53,101} Although 5-year overall survival rates have reached 60–80%, survivors often face a variety of long-term neurological, neuroendocrine, and social sequelae as a result of conventional treatment regimens (surgery, radiotherapy, and chemotherapy).^{40,46} It is therefore imperative for us to gain a better understanding of the genes driving medulloblastoma oncogenesis so that future targeted therapies that are more effective and less toxic can be made available.

Much of our current understanding of the molecular basis of medulloblastoma has been derived from insights into hereditary tumor syndromes¹⁵¹ and candidate gene approaches focused on developmental signaling pathways.^{60,96,170} For instance, individuals with Gorlin or Turcot syndrome possess germline mutations in the *PTCH1* and *APC* tumor suppressor genes, respectively, and are predisposed to medulloblastoma, among other cancers.^{6,51,62,63} Studies of the *PTCH1* gene in Gorlin syndrome and sporadic medulloblastomas, as well as knockout studies of its mouse homolog, *Ptc*, have helped to establish a role for aberrant SHH signaling in ~ 25–35% of medulloblastomas.^{55,96} Similarly, the identification of *APC* mutations in Turcot syndrome and more frequent mutations of *CTNGB1* in sporadic cases have implicated the Wnt signaling cascade in ~ 10–15% of patients with medulloblastomas.^{55,96} Furthermore, patients with Li-Fraumeni syndrome have germline *TP53* mutations and can have a broad spectrum of cancer types, including medulloblastoma.^{95,148}

Aside from what has been learned from the study of these familial tumor syndromes, the majority of additional oncogenes and tumor suppressor genes implicated in medulloblastoma have been discovered from a priori candidate gene selection. Mutational screening has further implicated additional SHH (*SUFU* and *SMO*) and Wnt (*AXIN1*) pathway genes.^{55,96} In addition, the Notch pathway is deregulated in a subset of human medulloblastomas and activated in certain mouse models.^{55,96} Furthermore, candidate epigenetic approaches have revealed hypermethylation of the promoter regions of known tumor suppressor genes: *HIC1*, *RASSF1A*, *CASP8*, and others.⁹⁰ The relevance of several of these genes has been further validated in mouse models of medulloblastoma.^{50,129,134} Although these single-gene and/or candidate-gene studies have shed significant light on our understanding of medulloblastoma pathogenesis, the candidates identified to date very likely represent only a small piece of the genomic puzzle responsible for the onset and progression of this pediatric tumor. Indeed, recent data from whole-genome sequencing projects of multiple tumor types implicate as many as 100 mutated genes per genome.^{78,125,173} If such estimates prove applicable to the medulloblastoma genome, many candidates have yet to be identified.

The goal of this review was to detail the progress that has been made in our understanding of the medulloblastoma genome over the last 20+ years, with specific emphasis on global, unbiased genomic profiling. Although what has been learned from gene- and pathway-specific studies of medulloblastoma has been indispensable to our knowledge of this disease, these findings will not be discussed in detail here but have been reviewed elsewhere.^{55,96} The

summary presented here describes how the technologies available to study the medulloblastoma genome have evolved over the last 2 decades (Fig. 1) and shows how much of the progress in this field has been dictated by both the size of the sample cohorts analyzed and the resolution of the technologies used in their study. A glimpse into what is to come in the near future of medulloblastoma genomics will also be discussed.

Early Cytogenetics and Karyotyping of Medulloblastoma

It has been over 20 years since G-banding was first used to disclose chromosomal abnormalities in medulloblastoma. It is a classic staining technique used to visualize a cell's karyotype, producing an alternating pattern of dark (heterochromatin) and light (euchromatin) bands along metaphase chromosomes.^{11,147} Early studies conducted at Duke University Medical Center and The Children's Hospital of Philadelphia provided original and informative descriptions of the medulloblastoma karyotype.^{17,19,59} Of significant interest, both of these groups reported an isochromosome of the long arm of chromosome 17 [i(17q)] as the most frequent structural abnormality and, in at least a few cases, the only aberration observed. Isochromosome 17q is the most common isochromosome in human cancer,¹⁰⁵ generating a net loss of 1 copy of the majority of 17p and a net gain of 1 copy of 17q (Fig. 2A). Frequent loss of heterozygosity on chromosome 17p in medulloblastoma was independently confirmed by multiple groups in the early 1990s, typically through deletion mapping by restriction fragment length polymorphism (RFLP) analysis.^{29,30,72,135,153} At present, cytogenetic aberrations affecting chromosome 17 remain the most common structural changes noted in medulloblastoma (Table 1);^{119,126,138} however, insight into the individual gene or combination of genes on this chromosome that drive tumorigenesis has not significantly improved since these early findings.

The establishment and cytogenetic characterization of permanent medulloblastoma cell lines and xenografts in the late 80s and early 90s also provided initial insight into the prevalence of oncogene amplification in medulloblastoma. Amplification of the *MYC* locus on 8q24, often in the form of double minutes, was reported in multiple cell lines and confirmed in primary tumors by several groups.^{8,18,48,130,157} The *MYC* family of protooncogenes (*MYC*, *MYCN*, and *MYCL1*) remain among the most prevalent targets of gene amplification in medulloblastoma (Fig. 2B).^{119,126}

The application of CGH to the cytogenetic characterization of medulloblastoma in the late 90s resulted in a much greater appreciation of the degree of genomic imbalance present in this cancer. Using CGH to profile a panel of 27 primary medulloblastomas, Reardon and colleagues¹³⁶ described frequent losses on chromosomes 10q, 11, 16q, 17p, and 8p as well as recurrent gains on chromosomes 7 and 17q. Several complementary follow-up studies based on a combination of G-banding, CGH, SKY, and FISH confirmed these now well-recognized regions of genomic instability in medulloblastoma and

Fig. 1. Timeline showing the evolution of genomic technologies over the last 2 decades and their application to the study of medulloblastoma. Dates reflect the application of referenced technologies to studies of the medulloblastoma genome. Listed below each time period is the approximate resolution (bp) of the techniques shown.

shed light on additional candidate regions.^{2,7,12,20,32,38,56,117} An innovative study involving members of our group retrospectively documented a series of 19 primary medulloblastomas (in addition to 5 sPNETs) using classic G-banding, FISH, CGH, and SKY.¹² Spectral karyotyping is a multicolored FISH procedure that permits the identification of structural rearrangements and origins of marker chromosomes in the genome in a single experiment.¹³ This “chromosome painting” technique is particularly useful for detecting structural aberrations lacking a net change in copy number, such as balanced translocations. The use of SKY in this study enabled the comprehensive identification of recurrent structural rearrangements in medulloblastoma, including those on chromosomes 7, 17, 3, 14, 10, and 22—something not possible through the use of G-banding or CGH alone.

Although these cumulative efforts provided the pediatric brain tumor community with relatively detailed summaries of the medulloblastoma karyotype, not until the advent of new technologies capable of detecting copy number changes at a much higher resolution could novel

candidate oncogenes and tumor suppressors in medulloblastoma be more efficiently identified through the use of genomics. Over the past 5 years, novel, high-resolution (that is, submegabase) genomic technologies have become available.^{34,112,147} The applications of some of these technologies in studies of the medulloblastoma genome are discussed in detail below.

High-Resolution Analysis of Medulloblastoma: Digital Karyotyping, aCGH, and SNP Genotyping Arrays

High-resolution genomic profiling of medulloblastoma has recently implicated multiple candidate oncogenes that are recurrently amplified in this malignancy (Table 2). In 2005, 2 very similar but independent studies led by Greg Riggins²¹ and Hai Yan³⁵ used digital karyotyping to identify novel regions of copy number aberrations in the medulloblastoma genome. Digital karyotyping uses short sequence tags derived from specific genomic loci to provide a quantitative and relatively high-resolution profile

Fig. 2. Prominent genomic aberrations in medulloblastoma. **A:** Isochromosome 17q in medulloblastoma. Single-nucleotide polymorphism array copy number profile for a medulloblastoma patient with a characteristic i(17q) abnormality. Isochromosome 17q is the most common cytogenetic aberration in medulloblastoma, identified in ~30–40% of cases. This structural abnormality results in a net loss of 1 copy of chromosome 17p and a net gain in 1 copy of 17q. Chromosome 17p loss and q gain are indicated in the copy number plot with green and red arrowheads, respectively. **B:** The MYC family amplification in medulloblastoma. Single-nucleotide polymorphism array copy number output showing focal, high-level amplification of MYC (8q24, upper portion of B), MYCN (2p24, middle portion of B), and MYCL1 (1p34, lower portion of B) in primary medulloblastomas. The MYC family protooncogenes are collectively targeted for amplification in ~10% of primary medulloblastoma cases, more frequently than any other known oncogenes.

of copy number aberrations throughout the genome.^{87,168} Boon et al.²¹ karyotyped 5 medulloblastoma cell lines by sequencing ~200,000 genomic tags per genome, identifying amplification of the *OTX2* homeobox gene on chromosome 14q22 in the D487Med cell line. Using quantitative PCR, the authors confirmed recurrent amplification of *OTX2* in both medulloblastoma cell lines (D425Med) and primary tumors. In the parallel study published by Di et al.,³⁵ *OTX2* amplification was revealed in the D458Med cell line, also by digital karyotyping. In addition, by using data from SAGE libraries and quantitative RT-PCR, *OTX2* (homeobox protein OTX2) was shown to be specifically overexpressed in medulloblastomas, especially lesions of anaplastic histology, as compared with a wide variety of other malignancies. Furthermore, the inhibition of *OTX2* expression by siRNA-mediated knockdown or all-trans retinoic acid (ATRA) repressed medulloblastoma cell growth in vitro, suggesting that *OTX2* may

represent an attractive target for therapy, particularly in medulloblastomas of the anaplastic subtype.

Among the first authors to apply aCGH to medulloblastomas were Mendrzyk et al.,¹⁰⁴ who profiled 47 primary cases. These authors confirmed typical cytogenetic abnormalities including gains of chromosomes 17q, 7, and 1q as well as losses of 17p, 11p, 10q, and 8. Importantly, they also identified a minimal region of recurrent, high-level amplification targeting the *CDK6* protooncogene on chromosome 7q21.2. They validated *CDK6* copy number aberrations by using FISH and established a negative correlation between moderate-high *CDK6* protein expression and overall survival by measuring *CDK6* status on a medulloblastoma TMA.

Note that *FOXG1* is another candidate gene implicated in medulloblastoma pathogenesis given its recurrent gain on 14q12 as revealed by aCGH analysis.¹ Adesina et al.¹ have analyzed a small panel of medulloblastomas

Genomics of medulloblastoma

TABLE 1: Most prominent cytogenetic aberrations in medulloblastoma

Gains		Losses	
Chromosome	Frequency (%) [*]	Chromosome	Frequency (%) [*]
1q	19	8p	12
2p	20	9q	10
7	24	10q	18
17q	44	11p	14
i(17q)	30	16q	12
		17p	36

* Frequency based on results of 500,000 SNP array profilings of 122 primary medulloblastomas.

using a combination of conventional CGH (19 cases) and aCGH (9 cases) and reported a gain of the *FOXP1* locus in 6 of 9 cases in the test set and 55 of 59 cases in a validation series of tumors. Expression of *FOXP1* (forkhead box protein G1) correlated with the gene copy number and inversely correlated with p21 protein levels, a relationship that was strengthened in vitro as siRNA-mediated knockdown of *FOXP1* in DAOY medulloblastoma cells resulted in increased p21 expression.

Amplifications of *MYCL1*, *PDGFRA*, and *KIT*—all protooncogenes not previously reported to be targeted in medulloblastoma—were also noted using aCGH technology.¹⁰⁰ Amplicons targeting these cancer genes have since been observed in our SNP array studies and by others, suggesting that they are relevant oncogenes in medulloblastoma.^{92,119}

An earlier aCGH study of medulloblastoma focused on a series of 16 primary cases and 3 medulloblastoma cell lines.⁷⁰ The authors noted a novel region of homozygous deletion on chromosome 6q23 in the DAOY cell line that targeted only 2 previously uncharacterized genes, both of which exhibited reduced expression in a large percentage of primary medulloblastomas analyzed. Our group has since validated this region of homozygous deletion in DAOY and functionally confirmed *L3MBTL3* as a putative medulloblastoma tumor suppressor gene mapping to this locus.¹¹⁹

Medulloblastomas can be histologically classified into 5 recognizable subtypes: classic, desmoplastic, anaplastic, large-cell, and medulloblastoma with extensive nodularity.⁵⁵ Classic medulloblastoma is by far the most common, followed by the desmoplastic subtype, which makes up ~ 10–20% of cases, and large-cell and anaplastic tumors, which account for ~ 5–10% of cases. Although there is considerable variability in terms of patient outcome between the different histological subtypes and although histological staging has proven to be a less than ideal method of stratification, there is a great deal of interest in defining their molecular basis. To gain an improved understanding of the genomics of desmoplastic medulloblastomas, Ehrbrecht et al.³⁹ performed conventional CGH on a set of 22 sporadic cases of this subtype, followed by aCGH on a subset. In their analysis, novel regions of amplification were reported on chromosomes 9p and 17q22–24, implicating candidate oncogenes in

TABLE 2 : Candidate oncogenes recurrently amplified in medulloblastoma

Gene	Cytoband	Reference(s)
<i>MYCL1</i>	1p34.2	82, 92, 100, 119
<i>MYCN</i>	2p24.3	82, 119, 126, and many others
<i>PDGFRA</i>	4q12	100, 119
<i>KIT</i>	4q12	100, 119
<i>TERT</i>	5p15.33	38, 136
<i>CDK6</i>	7q21.2	104, 119
<i>MYST3</i>	8p11.21	119
<i>MYC</i>	8q24.21	82, 119, 126, and many others
<i>JMJD2C</i>	9p24.1	39, 119
<i>miR-17/92</i>	13q31.3	118, 119
<i>IRS2</i>	13q34	119
<i>FOXP1</i>	14q12	1
<i>OTX2</i>	14q23.1	21, 35, 119

these regions. Notably, *JMJD2C* was suggested as a putative oncogene mapping to the amplified region found on 9p, and we have since identified it as recurrently amplified and overexpressed in an independent sample cohort and affecting the state of methylation on histone lysines in normal progenitor cells of the developing cerebellum (that is, CGNPs).¹¹⁹

There have been an impressive number of inquiries into the relationship between developmental signal transduction pathways and their role in medulloblastoma. Mutations in the Wnt, SHH, and Notch pathways have been well described in the medulloblastoma literature.^{55,96} Nonetheless, a comprehensive understanding of how specific genomic events contribute to aberrant signaling of these pathways has not been established. An important finding relevant to deregulated Wnt signaling in medulloblastoma was reported in 2006 in 2 independent but related studies.^{28,154} Clifford et al.²⁸ have profiled 19 primary medulloblastomas by aCGH, with the specific intent to genomically describe tumors with Wnt pathway activation (nuclear β -catenin; *CTNNB1* or *APC* mutation). Interestingly, in both the initial cohort (19 cases) and a validation series (32 cases), a single copy deletion of chromosome 6 (monosomy 6) was found exclusively in the Wnt pathway tumors. Identical findings were reported by Thompson et al.,¹⁵⁴ who consistently observed a correlation between the Wnt pathway signature (Wnt pathway expression; *CTNNB1* mutation) and markedly reduced expression of genes mapping to chromosome 6 because of deletion. Monosomy 6 is now widely accepted in the medulloblastoma community as a genomic marker of Wnt pathway tumors that is consistently associated with *CTNNB1* mutation.^{43,82,154} From a clinical perspective, monosomy 6/*CTNNB1* mutation is among the most reliable genetic markers in medulloblastoma, correlating with a highly favorable prognosis.^{28,43,52,126} Indeed, 100% of patients found to belong to the Wnt immunohistochemical category in the recent St Jude Medulloblastoma-96 clinical trial were event free at 5-years, compared with only 65% of patients in the SHH category.⁵²

FIG. 3. Scatterplot identifying reports in the literature that have profiled medulloblastoma copy number aberrations using array-based genomic technologies. Each publication is represented as a colored circle, with its position along the y axis determined by the number of samples analyzed and its position along the x axis determined by the approximate median resolution of the array platform(s) used in the study. Study referred to in figure is Northcott et al., 2009.¹¹⁹

Very recently, Pfister and colleagues¹²⁶ proposed a model for molecular risk stratification of pediatric medulloblastoma based on DNA copy number aberrations affecting chromosomes 6q, 17q, and *MYC/MYCN* loci. Using aCGH, the authors initially profiled 80 primary medulloblastomas in an attempt to identify genomic aberrations of prognostic value, and found a gain of chromosome 6q, amplification of *MYC* and *MYCN*, isolated gain of 17q, and i(17q) all to be associated with a poor clinical outcome. In contrast, the loss of chromosome 6q was indicative of an excellent prognosis, consistent with findings in the current literature.^{28,43} Validation of these prognostic markers in a nonoverlapping set of 260 primary cases by using interphase FISH on a medulloblastoma TMA, Pfister et al. were able to establish an elegant staging system whereby patient outcome could be predicted based on the genomic status of only 4 markers (arranged from worst to best outcome): *MYC/MYCN* amplification, 6q gain, 17q gain, 6q/17q balanced, and 6q loss.

Although several of the aCGH studies described above have been informative and have enhanced our understanding of the medulloblastoma genome, most have

profiled relatively modest sample cohorts (median sample size: ~ 24 cases) using arrays that—although an improvement over classic CGH—are of insufficient density and thus resolution (median resolution ~ 500 kb) to detect very focal genetic events. To address these caveats, we retrospectively collected an unprecedented cohort of 201 fresh-frozen primary medulloblastomas and 11 medulloblastoma cell lines and analyzed their genomes using high-resolution SNP genotyping arrays.¹¹⁹ These oligonucleotide arrays consisted of 25mer probes designed to detect the genotype (that is, A or B allele) of known SNPs at loci distributed across the genome.^{69,85,98,99} The median intermarker distances (that is, resolution) of probes on the 100,000 and 500,000 arrays used in this study were 8.5 and 2.5 kb, respectively, which are at least an order of magnitude higher in terms of resolution than any previous array-based study of the medulloblastoma genome (Fig. 3). In addition to reporting cytogenetic gains and losses at frequencies already known in medulloblastoma (Fig. 4 and Table 1), this strategy of profiling a large number of samples on a high-resolution platform led to the identification of 191 high-level amplifications and 159 homozy-

Fig. 4. Visual representation of gains and losses in the genome of medulloblastoma. High-resolution copy number data derived from 122 primary medulloblastomas is represented as a histogram for each of the 22 autosomes, with the relative frequency of gain depicted on the right of each chromosome in *red*, and the frequency of losses shown on the left of each chromosome in *blue*. The most frequent cytogenetic gains in this representative cohort are localized to chromosomes 1q, 7, and 17q, whereas recurrent losses are most notable on chromosomes 8, 9q, 10q, 11, 16q, and 17p.

gous deletions, most of which had not been reported in medulloblastoma. Surprisingly, only 12 recurrent amplifications were identified, and a mere 6 homozygous deletions were found in more than 1 sample. Of the recurrent homozygous deletions, *EHMT1*, a euchromatic histone (H3K9) methyltransferase, was the lone gene mapping to the minimal common region of a deleted region on chromosome 9q34, suggesting that it may represent a novel tumor suppressor gene in medulloblastoma. Note that *EHMT1* functions as part of a transcriptional repressor complex that mediates gene silencing by promoting dimethylation of H3K9 (H3K9me²),^{121,150} a repressive epigenetic modification,^{16,84} in the promoter regions of target genes. The expression of *EHMT1* was shown to be significantly downregulated at both the mRNA and protein level, and staining for both *EHMT1* and H3K9me² on a medulloblastoma TMA showed a significant correlation between *EHMT1* status and the H3K9 methylation state, consistent with a model in which the loss of *EHMT1* leads to H3K9 hypomethylation in medulloblastoma. In

addition to *EHMT1*, 7 other genes with a putative role in the regulation of histone lysine methylation were also found to be the target of focal copy number aberrations in the data set, including *SMYD4*, *L3MBTL2*, *L3MBTL3*, *SCML2*, *JMJD2C*, *JMJD2B*, and *MYST3*. Recurrent targeting of genes sharing a common role in the modulation of histone lysine residues in medulloblastoma suggests that deregulation of the histone code, particularly histone lysine methylation, very likely contributes to the pathogenesis of at least some medulloblastomas.

Medulloblastoma Transcriptome Profiling

Typically, strategies aimed at the transcriptional profiling of cancer have involved the comparison of gene expression signatures obtained for normal and neoplastic tissues (Fig. 5). In one of the earliest studies of medulloblastoma gene expression profiling, Michiels et al.¹⁰⁷ used SAGE to compare genes expressed in medulloblastoma

Fig. 5. Heatmap showing gene expression data for 10 normal cerebellum (CB) samples (5 fetal and 5 adult) and 50 primary medulloblastomas analyzed using Affymetrix arrays. Genes exhibiting elevated expression are shown in *red*, whereas genes with reduced expression are depicted in *green*. Unsupervised hierarchical clustering of samples using the most differentially expressed genes results in a clear distinction between normal cerebellar samples and primary tumors.

Fig. 6. Schematic illustrating how collaborative approaches that involve integration of genomics, transcriptome analysis, and epigenomics will be applied in the future characterization of medulloblastoma. For each category, some of the leading technologies of the present and future are listed, with applications relying on NGS (Next-Gen Sequencing) present in each. The union of these orthogonal genome/transcriptome/epigenome interrogation strategies will greatly accelerate the identification of novel candidate genes and pathways involved in medulloblastoma genesis and permit follow-up functional validation studies, correlation with clinical variables, and improved molecular classification.

with those in the fetal brain (24.5 weeks). Serial analysis of gene expression uses DNA sequencing technology to digitally quantify mRNA abundance by counting the frequency with which a short sequence tag (that is, transcript) appears in a cDNA library.^{161,162} Serial analysis of gene expression technology is very effective in quantifying gene expression and in identifying novel genes/transcripts, as no a priori knowledge of the genome under study is required.^{131,144,159,160} In the study by Michiels and colleagues, ~ 10,000 tags were sequenced in both medulloblastoma and fetal brain, with ~ 6000 unique genes identified in each transcriptome. A comparison of the SAGE data revealed 138 genes with significant differential expression between the 2 sources, including ZIC1 (zinc finger protein ZIC 1) and OTX2, both showing significantly elevated expression in medulloblastoma that was confirmed by Northern blotting in multiple independent samples. As these genes are highly expressed in cerebellar germinal zones (that is, the external granule layer and subventricular zone), this study provided early clues into the origins of medulloblastoma.

The presence of disseminated disease at diagnosis is a strong, independent indicator of a poor prognosis for medulloblastoma, occurring in ~ 1 of every 3 cases.^{52,83,152,177} Therefore, understanding the molecular basis of metastatic medulloblastoma is extremely important clinically. The first study to specifically compare metastatic (M+) with nonmetastatic (M0) medulloblastoma at a gene expression level was performed by MacDonald and colleagues in 2001.⁹⁴ Twenty-three primary medulloblastomas designated as either M+ or M0 were analyzed using Affymetrix G110 cancer arrays, which identified 85 genes as differentially expressed between the 2 classes. Using a supervised class prediction algorithm, this 85-gene signature classified the M+ and M0 tumors with 72% accuracy. Interestingly, PDGFR and members of the Ras/MAPK signaling cascade were reported to be significantly upregulated in metastatic versus nonmetastatic cases. The overexpression of PDGFR in metastatic disease was confirmed by immunohistochemistry in an independent set of tumors. In vitro assays performed in the DAOY medulloblastoma cell line showed that the

PDGF ligand activated the Ras/MAPK pathway and promoted cell migration in this system, whereas neutralizing antibodies against PDGFR attenuated MAPK signaling and prevented ligand-mediated migration. In a follow-up study by Gilbertson and Clifford,⁵⁴ the association between PDGFR overexpression and metastatic medulloblastoma was confirmed, further supporting the validity of this pathway as a candidate for targeted therapy.

Undoubtedly, one of the most seminal papers in medulloblastoma genomics was written by Pomeroy and colleagues,¹³² who surveyed the expression profiles of a large series of primary brain tumors and made at least 3 findings of clinical significance. Initially, 42 samples consisting of medulloblastomas (10 patients), atypical teratoid rhabdoid tumors (5 patients), renal and extrarenal rhabdoid tumors (5 patients), sPNETs (8 patients), and nonembryonal brain tumors (malignant glioma; 10 patients), and normal human cerebellum (4 patients) were analyzed using Affymetrix HuGeneF1 arrays containing ~ 6000 known genes. Based on differentially expressed transcripts, these authors showed a clear distinction between the different tumor types, establishing that histologically similar tumors such as medulloblastomas and sPNETs were molecularly distinct. The molecular distinction between medulloblastomas and sPNETs has important clinical implications; because of their similar histology, these tumors were historically classified under the same broad category of PNET and thus were treated with the same protocols.¹⁴¹ In recent years, however, it has become evident that medulloblastomas and sPNETs are both molecularly and biologically distinct, with sPNETs typically exhibiting a worse prognosis.^{31,89,100,127,137,155}

These same authors also compared the expression profiles in a set of 34 medulloblastomas of either classic (25 cases) or desmoplastic (9 cases) histology, revealing a notable degree of statistically significant differential expression between the 2 subtypes. Genes signifying desmoplastic medulloblastoma included *PTCH*, *GLI*, *MYCN*, and *IGF2*, all of which are now well-described targets of SHH signaling. Although a link between mutations in the SHH pathway and medulloblastoma pathogenesis had already been discovered, this study was among the first to document an association between aberrant SHH signaling and sporadic desmoplastic medulloblastoma.

A third key finding in this study stemmed from the authors' use of gene expression data to predict the outcome of 60 patients with medulloblastoma for whom clinical follow-up data were available. Using a class prediction algorithm, an 8-gene classification model was generated and successfully predicted the survival status for 47 of the 60 patients profiled. Genes correlated with a favorable outcome included markers of cerebellar differentiation (β -*NAP*, *NSCL1*, and *TRKC*) as well as genes encoding components of the extracellular matrix (lysyl hydroxylase [*PLOD*], collagen Type *V α i*, and elastin). In contrast, genes associated with a poor outcome included those with a role in cell proliferation and metabolism (*MYBL2*, enolase 1, *LDH*, *HMG1/Y*), and cytochrome C oxidase) as well as ribosomal protein-encoding genes. Much like the study by MacDonald et al.⁹⁴ described earlier, the report

by Pomeroy and colleagues¹³² demonstrates the utility of correlating gene expression profiles in medulloblastoma with a particular phenotype (that is, favorable vs poor outcome) and provides a rationale for the incorporation of similar molecular profiling strategies in the future diagnosis and treatment of patients with medulloblastoma.

Following the Pomeroy study, a number of independent groups, including our own, have engaged in medulloblastoma transcriptome profiling efforts using a variety of technologies.^{22,79,115,123,175} Boon et al.²² used SAGE to analyze 20 primary medulloblastomas, identifying 30 transcripts exhibiting elevated expression in tumors compared with normal cerebellum and additional regions of the brain. The cancer-testis antigen *PRAME*, *CD24*, *PRL*, *TOP2A*, *MYCN*, and *BARHL1* were all overexpressed in this study. Data from more recent array-based studies by our group have confirmed the aberrant expression of cancer-testis antigens from the *MAGE* and *GAGE* families in medulloblastoma cell lines and in some primary samples, suggesting that these genes may be important in medulloblastoma.⁷⁹

In an earlier study we used suppression subtractive hybridization to identify genes deregulated in both human and mouse (*Ptc^{+/-}*) medulloblastoma compared with normal, species-matched cerebellum.¹⁷⁵ In suppression subtractive hybridization, double-stranded cDNA libraries are first prepared from tester (that is, medulloblastoma) and driver (that is, normal cerebellum) RNA samples.¹⁶⁴ Heat-denatured tester cDNA is subsequently digested, adapter ligated, and then hybridized with the denatured driver cDNA to generate a subtracted cDNA library that is PCR amplified and cloned into a recipient plasmid for bacterial transformation and sequencing of clones for gene identification. In this effort, over 100 upregulated cDNA fragments were identified in the human library, including *ULIP* (also known as *DPYSL3*), *SOX4*, *NNAT*, and the previously implicated *BARHL1* and *OTX2* genes. In addition, genes identified as upregulated in medulloblastomas from *Ptc^{+/-}* mice included *CCND2*, *TMPO*, *Musashi-1*, and others.

Another informative expression profile of medulloblastoma was generated by Neben et al.,¹¹⁵ who analyzed ~ 4200 genes in 35 primary medulloblastomas in an attempt to identify those associated with patient outcome. Based on mRNA levels, 54 genes were shown to be markers of poor outcome, and a subset of these (9 genes) was further evaluated by immunohistochemistry in a nonoverlapping set of 180 cases on a medulloblastoma TMA. Of these candidate genes, *STK15* positivity was identified as a negative prognostic marker of overall survival, whereas other putative markers implicated in the study (that is, cyclin D1 and stathmin 1) were not.

Molecular Classification of Medulloblastoma

Over the past decade, significant progress has been made in how we study the cancer genome. Indeed, gene expression profiling has proven to be an effective tool for the molecular classification of cancer, including brain tumors.^{57,109,120,132} Following the studies of MacDonald and Pomeroy, Thompson et al.¹⁵⁴ were the first to truly

Genomics of medulloblastoma

establish the existence of unique molecular subgroups of medulloblastoma using gene expression data. Profiling a series of 46 primary medulloblastomas, these authors performed unsupervised hierarchical clustering with the most informative genes in the data set, identifying 5 molecular subgroups of medulloblastoma. By integrating immunohistochemistry, FISH, and mutational screening data generated from these samples, it was shown that molecular subgroups of medulloblastoma have specific genomic and genetic features. Importantly, this study was the first to demonstrate that Wnt (that is, monosomy 6 and *CTNNB1* mutation) and SHH tumors (that is, *PTCH1* and *SUFU* mutation) are mutually exclusive.

In a more recent study, Kool et al.⁸² utilized a similar integrative genomics approach to further characterize molecular subgroups of medulloblastoma. By combining array-based gene expression and copy number profiles for 52 primary cases, Kool and colleagues recapitulated the 5 molecular subgroups described by Thompson et al.¹¹ and correlated the different subgroups with specific genomic and clinical features. Importantly, the authors furthered our knowledge of non-Wnt/SHH tumors (subgroups A and B), showing that the 3 remaining subgroups (C, D, and E) are closely related and marked by elevated expression of neuronal differentiation (subgroups C and D) and retinal (subgroups D and E) genes. Furthermore, metastatic disease was shown to be more highly associated with subgroups C, D, and E, providing further support for the potential stratification of patients based on molecular subgrouping.

Beyond Protein-Coding Genes: miRNAs in Medulloblastoma

Over the course of the past 5 or so years, there has been a literal explosion in the miRNA field, especially with respect to elucidating their role in human disease—in particular, cancer.^{24,41,64} Small, noncoding, single-stranded RNA molecules, miRNAs posttranscriptionally regulate gene expression through their interaction with complementary sequences in the 3' untranslated regions of target mRNAs.^{3,10} Target mRNAs are either degraded or translationally repressed by specific miRNAs, depending on the degree of complementarity between the miRNA and its target. Despite an intense amount of investigation into the involvement of miRNAs in a variety of cancer types, knowledge of their role in medulloblastoma pathogenesis is still in its infancy. The few studies of the entire miRNAome that have been conducted to date are discussed below.

Ferretti and colleagues⁴⁵ recently performed a TaqMan quantitative RT-PCR-based profiling of 248 miRNAs in a panel of medulloblastomas (14 cases) and normal cerebellar controls (7 cases), reporting an overwhelming bias toward downregulation of miRNAs in tumors versus controls. A subset of 86 miRNAs previously reported to be expressed in neuronal tissues and/or implicated in cancer were further analyzed in a larger cohort of tumors (34 cases), with the authors selecting miR-9 and miR-125a as 2 neuronal candidates downregulated in medulloblastoma for functional studies. The expression of both miR-9

and miR-125a was induced by retinoic acid treatment of D283 medulloblastoma cells, an agent known to inhibit medulloblastoma cell proliferation. In addition, ectopic overexpression of miR-9 and miR-125a inhibited proliferation, impaired anchorage-independent growth, and promoted apoptosis of D283 cells. Truncated *trkC* was identified as a target for posttranscriptional repression by both miR-9 and miR-125a in this study, suggesting a possible correlation between the loss of miR-9/miR-125a and the upregulation of the proproliferative truncated *trkC* in medulloblastoma.

In an effort to discriminate miRNAs deregulated in SHH-driven medulloblastomas from non-SHH cases, the same group of authors⁴⁴ used the *Gli1* expression status to stratify a panel of 31 medulloblastomas into 2 classes (*Gli1*^{high} and *Gli1*^{low}) before profiling a set of 250 miRNAs using TaqMan-based quantitative RT-PCR. This approach revealed a set of 34 miRNAs exhibiting significant differential expression between the 2 classes. Three candidates exhibiting reduced expression in *Gli1*^{high} tumors—miR-125b, miR-324-5p, and miR-326—were chosen for functional analysis based on their predicted capacity to target and repress the SHH family members, *Smo* and *Gli1*. Indeed, all 3 candidates were shown to repress *Smo* mRNA levels when overexpressed in DAOY medulloblastoma cells. Additionally, the expression of these candidate miRNAs correlated with the differentiation state of cultured CGNPs, presumed cells of origin for SHH-driven medulloblastomas,^{14,47,55} and their ectopic expression reduced SHH-mediated proliferation and promoted neurite outgrowth in the same cell type.

In 2 distinct but parallel comprehensive analyses of the human and mouse medulloblastoma miRNAomes, the *miR-17/92* polycistron was identified as a putative medulloblastoma oncogene.^{118,158} A bona fide oncogene in B-cell lymphoma, *miR-17/92* has been reported to be aberrantly expressed in a variety of human tumors.^{66,103} To identify miRNAs deregulated in mouse models of medulloblastoma, Uziel et al.¹⁵⁸ performed unbiased NGS to quantify miRNA abundance in medulloblastoma cells isolated from spontaneous tumors of *Ink4c*^{-/-}; *Ptc*^{+/-} or *Ink4c*^{-/-}; and *p53*^{-/-} genotypes as compared with wild-type control cerebellum (1 month old) and CGNPs (6 days old). This strategy revealed 26 miRNAs with elevated expression and 24 with reduced expression in the tumor models. Among upregulated miRNAs in murine medulloblastoma cells, miR-17/92 and related paralogs accounted for 9 of 26. In addition, the authors provided evidence that miR-17/92 might cooperate with SHH signaling in medulloblastoma, showing preferential upregulation of miR-17/92 in the SHH subtype by quantitative RT-PCR profiling of a small panel of human tumors (5 SHH lesions and 5 non-SHH lesions). To evaluate its oncogenic potential in a context relevant to SHH-driven medulloblastoma, miR-17/92 was retrovirally transduced into 6-day-old CGNPs isolated from both *Ink4c*^{-/-}, *Ptc*^{+/-} and *Ink4c*^{-/-}, *p53*^{-/-} mice prior to orthotopic transplantation of miR-17/92-expressing CGNPs into immunocompromised mice. Notably, only cells derived from the *Ptc*^{+/-} background developed medulloblastoma (9 of 9 cases) in this model. Furthermore, tumor cells were sensitive to

the Smo inhibitor cyclopamine, exhibited elevated *Math1* and *Gli1* mRNA levels, and lost expression of the wild-type *Ptc* allele—all markers of activated SHH signaling and supportive of a synergistic connection between miR-17/92 and SHH in these tumors.

As detailed earlier, we recently performed high-resolution SNP array profiling on a group of > 200 medulloblastomas.¹¹⁹ This effort revealed multiple regions of previously unreported copy number aberrations in the medulloblastoma genome, including recurrent, high-level amplification of *miR-17/92* on chromosome 13q31.^{118,119} Subsequent interphase FISH performed on a medulloblastoma TMA consisting of a nonoverlapping series of tumors confirmed *miR-17/92* amplification in ~ 6% of cases. To gain further insight into the role of miRNAs in medulloblastoma, we next used miRNA microarrays to globally profile the human medulloblastoma miRNAome in a series of 90 primary medulloblastomas and 10 normal cerebellar controls (5 fetal and 5 adult samples). Remarkably, miR-17/92 and related paralogs (miR-106a/363 and miR-106b/25) were identified as the most highly upregulated miRNAs in medulloblastoma when compared with normal cerebellum in this analysis. The combination of miR-17/92 amplification and consistent overexpression suggested miR-17/92 as a key player in medulloblastoma pathogenesis.

As shown by the aforementioned studies of Thompson¹⁵⁴ and Kool,⁸² medulloblastomas can be classified into unique molecular subgroups based on distinct gene expression signatures and specific genomic and genetic features.^{82,154} Using Affymetrix exon arrays to comprehensively profile the transcriptome of the same 90 primary medulloblastomas analyzed by miRNA microarray, we described 4 distinct molecular subgroups of medulloblastoma.¹¹⁸ These subgroups include the well-characterized Wnt and SHH subgroups described earlier, as well as 2 independent subgroups we have designated Groups C and D. Through the integration of genomics (copy number), mRNA, and miRNA expression, we found that miR-17/92 was most highly expressed in SHH-driven medulloblastomas, in agreement with the observations reported by Uziel and colleagues.¹⁵⁸ Additionally, we showed elevated miR-17/92 levels in tumors exhibiting high MYCN (SHH) and MYC (Group C, Wnt) expression, indicative of miR-17/92 transcriptional upregulation by N-Myc and Myc and confirming miR-17/92 aberrancy in a large percentage of human medulloblastomas (~ 60%). Deregulation of miR-17/92 was conserved in well-characterized, SHH-driven mouse models of medulloblastoma—*Ptc*^{+/-} and *SmoA1*—also in concordance with the findings mentioned above. Finally, using CGNPs isolated from wild-type mice, we showed that miR-17/92 is transcriptionally induced by SHH through N-Myc, maintains CGNPs in a proliferative state in the absence of SHH, and synergizes with SHH to enhance CGNP cell growth. Cumulatively, the results of Uziel et al. and our own strongly support miR-17/92 as a legitimate medulloblastoma oncogene that cooperates with SHH signaling to promote and/or enhance CGNP proliferation.

Beyond Genomics: the Medulloblastoma Epigenome

Until recently, the majority of cancer research efforts had focused on describing the genetic basis of cancer, studying everything from large cytogenetic aberrations to SNPs and mutations. Over the past few years, however, there has been an ever-growing volume of literature linking the deregulation of epigenetics to malignancy.^{23,42,75,76,156} Epigenetics is defined as “mitotically heritable changes in gene expression that are not accompanied by modifications in primary DNA sequence.” Epigenetic modifications include DNA methylation on cytosine residues, most often in the context of CpG dinucleotides, as well as posttranslational modification of histone proteins, such as methylation, acetylation, phosphorylation, and ubiquitination.^{16,84} Hypermethylation of CpG islands located at the 5' end of genes has been reported in most cancers and, either alone or in combination with genetic mechanisms (that is, gene deletion or mutation), can contribute to tumor suppressor gene silencing. Although a handful of known tumor suppressors can be silenced by promoter methylation in medulloblastoma by using candidate gene approaches (that is, *HIC1*, *RASSF1A*, and *CASP8*),^{58,61,65,68,91,93,140,166} the application of unbiased, whole-genome strategies to identify novel candidates have been scant to date, consisting of only those instances described in the few published reports mentioned below.

Among the earliest studies to implicate aberrant promoter methylation in medulloblastoma on a global scale was an effort led by Frühwald and colleagues⁴⁹ who used the technique of restriction landmark genomic scanning to analyze DNA methylation patterns in 17 primary medulloblastomas and 5 medulloblastoma cell lines. Using this method, the authors identified methylation in up to 1% of all CpG islands in primary tumors and up to 6% in medulloblastoma cell lines. In addition, an association between hypermethylated sequences in medulloblastoma and a poor prognosis was implied. Collectively, these findings provided early evidence that epigenetic events are likely to play a role in medulloblastoma pathogenesis.

In a study using microarray-based differential methylation hybridization, Waha et al.¹⁶⁵ identified hypermethylation of the *SCG5* (secretory granule, neuroendocrine protein 1 [7B2 protein] gene) in 16 (~ 70%) of 23 primary medulloblastomas and 7 (~ 87%) of 8 medulloblastoma cell lines. Differential methylation hybridization involves a series of enzymatic digestions with methylation-insensitive followed by methylation-sensitive restriction enzymes, and uncut (methylated) fragments are PCR-amplified before hybridization to microarrays containing probes designed to interrogate CpG islands throughout the genome.¹⁷⁴ The expression of *SCG5* was found to be downregulated in the majority of primary samples and cell lines as compared with normal cerebellar controls, and *SCG5* transcription was restored in cell lines treated with the demethylating agent, 5-aza (5-aza-2'-deoxycytidine). Furthermore, the reexpression of *SCG5* in the D283Med cell line resulted in growth suppression and reduced colony formation, suggesting that *SCG5* may be a putative tumor suppressor gene in medulloblastoma.

Genomics of medulloblastoma

Pfister and colleagues¹²⁸ developed and applied a technique known as array-based profiling of reference-independent methylation status (aPRIMES) to globally survey DNA methylation patterns in the medulloblastoma genome. This technique compares 2 differentially digested (methylation-sensitive and methylation-specific) aliquots from the same sample genome by competitive hybridization to a CpG island microarray. The advantage of using test-versus-test as opposed to test-versus-control hybridization is the avoidance of both the influences of tissue-specific methylation that may be present in the control sample and the genomic aberrations that may exist in the test sample and not in the control genome. Using this methodology, Pfister et al. showed a striking association between samples classified as either “low methylators” or “high methylators” and patient outcome, with the high-methylator group exhibiting reduced overall survival. In addition, the GLI C2H2-type zinc-finger protein family member *ZIC2* was identified as a hypermethylated candidate using aPRIMES and was subsequently confirmed to be epigenetically silenced in a panel of primary medulloblastomas by using a combination of pyrosequencing and quantitative RT-PCR analysis.

In 2 technically similar yet independent genome-wide methylation studies conducted by Anderton et al.⁴ and Kongkham et al.,⁸¹ 5-aza-treated medulloblastoma cell lines were profiled on Affymetrix expression arrays in an effort to uncover novel tumor suppressor genes silenced by aberrant promoter methylation. In the report by Anderton and colleagues, 3 medulloblastoma cell lines (D425Med, D283Med, and MED8A) were either left untreated or exposed to 5-aza, and transcripts showing increased expression by microarray in response to the DNA methyltransferase inhibitor were investigated further by bioinformatically confirming the presence of a 5' CpG island and assessing methylation status through bisulfite sequencing.⁴ This approach combined with gene expression analysis identified *COLIA2* as an epigenetically silenced candidate in medulloblastoma that is preferentially inactivated in nondesmoplastic and noninfant (> 3 years) desmoplastic cases.

Kongkham et al.⁸¹ performed a similar genome-wide 5-aza screen in a larger group of 9 medulloblastoma cell lines but incorporated multiple additional criteria when filtering identified candidate genes as compared with those in the Anderton et al.⁴ study. These authors selected for further analysis those genes that demonstrated in at least 2 cell lines a > 2-fold upregulation in expression following 5-aza treatment, contained a predicted CpG island in their promoter region, and were identified as targets of loss of heterozygosity based on SNP genotyping studies.¹¹⁹ Under these criteria, *SPINT2*, a negative regulator of the HGF/Met signaling pathway, was identified, exhibiting robust reexpression in 6 of the 9 medulloblastoma cell lines profiled. The authors confirmed the downregulation of *SPINT2* in a significant percentage of primary medulloblastomas (> 2-fold in 41 of 56 samples) analyzed by quantitative RT-PCR, and, importantly, that aberrant promoter methylation (assessed by methylation-specific PCR) correlated with the observed reduction in gene expression in most cases. Stable reexpression of *SPINT2* in

medulloblastoma cell lines resulted in the attenuation of the malignant phenotype, inhibiting cell proliferation, anchorage-independent growth in soft agar, and cell motility. Furthermore, the orthotopic transplantation of D283 cells stably reexpressing *SPINT2* into recipient nude mice significantly delayed the time to death compared with empty vector control cells in an intracerebellar xenograft model. These data strongly implicate *SPINT2* as a putative tumor suppressor gene in medulloblastoma and shed further light on the apparent role of aberrant HGF/Met signaling in medulloblastoma etiology.

Collectively, these recent studies of the medulloblastoma epigenome have proven informative and have further implicated epigenetic gene silencing as an important mechanism of tumor suppressor gene inactivation in medulloblastoma. The future application of strategies that enrich for epigenetic modifications (that is, methylation-dependent immunoprecipitation [MedIP] or chromatin immunoprecipitation [ChIP]) combined with high-resolution microarrays or NGS technologies will probably lead to an improved appreciation of the role that epigenetics plays in medulloblastoma.

Next-Generation Genomics of Medulloblastoma

Over the past few years, microarray technologies have significantly increased our understanding of the medulloblastoma genome, transcriptome, and, to some extent, epigenome. Moving forward, array platforms will undoubtedly continue to be used in genome-wide profiling of medulloblastoma, especially as the resolution and coverage of these methods continue to improve and the cost of these screens remains affordable. However, recent breakthroughs in DNA sequencing technologies have taken the genomics community by storm, and their application in medulloblastoma research is, without question, imminent.

Since the early 1990s, the capillary-based Sanger method of DNA sequencing has been the mainstay for most applications in molecular biology, even the first drafts of the human genome published in 2000.^{86,163} More recently, conventional sequencing has been successfully used in large-scale resequencing efforts, profiling anywhere from a few hundred genes to all known protein-coding genes in a single cancer genome.^{26,36,77,78,125,173} Indeed, initial exon resequencing of the colorectal, breast, pancreatic, and glioblastoma multiforme genomes has revealed new genes and pathways involved in the pathogenesis of the respective cancer types.^{77,78,125,173} However, these studies relied on the PCR-mediated amplification of literally hundreds of thousands of exons combined with an enormous workload of conventional sequencing, unrealistic tasks for most of the cancer genomics community.

Fortunately, over the last few years a revolution in DNA sequencing technology has occurred and is rapidly changing the field of cancer genomics.^{33,143,145,146} Next-generation (also known as “next-gen” or “deep”) sequencing biochemistries now permit the parallel acquisition of up to 10s of gigabases (Gb) of DNA sequence of variable “read” length in a single experiment. Multiple NGS options are currently available—454 genome sequencer

(Roche), gene analyzer (Solexa/Illumina), SOLiD system (Applied Biosystems)^{5,146}—each with its own strengths and weaknesses. The repertoire and capabilities of these platforms are continually improving. For example, the SOLiD 3 System currently boasts > 20 Gb of DNA sequence per run, compared with ~ 750–1000 bp generated using traditional Sanger sequencing. Although the cost/base ratio is significantly lower for next-generation technologies, the current cost of a single SOLiD 3 run is in the neighborhood of \$15,000 (vs ~ \$5 for conventional sequencing), making next-generation tools prohibitively expensive for a large percentage of the research community, especially when considering the sequencing of large numbers of patient samples.

The biochemistry and real-time imaging-based data acquisition involved in NGS are what allow these technologies the parallel, high-throughput capacity that is not feasible with conventional Sanger sequencing; detailed reviews on the technical principles of conventional sequencing and NGS have been reported.^{5,106,111,146} In the Sanger method, DNA to be sequenced is either randomly fragmented and cloned into a high-copy number plasmid prior to bacterial transformation (shotgun sequencing) or PCR-amplified using target-specific primers (gene-specific sequencing). The amplified template is then subjected to a series of sequencing cycles whereby the template is denatured, primers are annealed, and a new complementary strand is synthesized in the presence of fluorescently labeled dideoxynucleotide triphosphates (ddNTPs), 1 unique color for each of the 4). End-labeled DNA fragments are subsequently separated using high-resolution capillary electrophoresis followed by laser excitation of labeled fragment ends, with the emission spectra producing a 4-color chromatogram that can be translated into DNA sequence. Modern Sanger sequencing units can simultaneously run samples in 96- or 384-well format, generating reads of up to 1000 bp in length per sample and providing some degree of throughput.

Despite differences in template amplification and sequencing biochemistry associated with current next-generation platforms, the principles and workflow involved in these technologies are relatively similar. Initially, a template library is prepared through random DNA fragmentation and adapter ligation. Ligated fragments are then bound to micron-sized beads (Roche and Applied Biosystems) or a planar substrate (Solexa/Illumina) and PCR amplified (that is, emulsion PCR or bridge PCR) as clusters or colonies consisting of thousands of clonal “features” to be sequenced. An array or flow-cell can consist of literally millions of clustered features, enabling massively parallel downstream sequencing. So-called sequencing-by-synthesis is then performed with either a polymerase (Roche and Solexa/Illumina) or ligase (Applied Biosystems) that serially extends primed templates. Light (pyrosequencing with Roche) or fluorescence (Solexa/Illumina and Applied Biosystems) emitted following the incorporation of dNTPs (deoxynucleoside triphosphates) or oligonucleotides is then captured by imaging the full array of synthesized features at the end of each cycle. The final result of a full next-generation run currently ranges from up to ~ 1,000,000,000 reads of ~ 400

bp with Roche, ~ 150,000,000 reads of 35 bp with Solexa/Illumina, and ~ 300,000,000 reads of 50 bp with the Applied Biosystems. These figures translate into 10s of Gb of DNA sequence in a single run (1 human genome comprises ~ 3 Gb), allowing for high-coverage, whole-genome sequencing on 1 machine within a few weeks—this in sharp contrast to the sequencing “factories” and several years required for the initial Sanger-based sequencing of the human genome not more than a decade ago.

Multiple “proof-of-principle” studies using next-generation technology have now been performed to analyze the various aspects of both normal and cancer genomes. Published reports have described array-based, targeted capture, and NGS of ~ 200,000 protein-coding exons in the human genome, allowing specific identification of both common and rare sequence variants.^{67,116} Unbiased, whole-genome NGS has also been reported for multiple normal human genomes^{15,80,167,171} and, recently, the acute myeloid leukemia genome from a single individual.⁸⁸ Producing nearly 100 billion bases of sequence, authors of the acute myeloid leukemia study described 10 genes with acquired somatic mutations that were not present in the patient-matched genome from normal skin cells.

Perhaps equally impressive, NGS has not been limited to studies aimed at the identification of sequence variants and mutations.^{5,111} Structural aberrations, including inter- and intrachromosomal rearrangements (inversions, inverted/tandem duplications, and translocations) as well as copy number aberrations (amplifications and deletions), have been identified in human cancer cells using NGS, with improved specificity and sensitivity compared with array-based methods.^{25,27} Whole-transcriptome profiling (also known as RNA-Seq) has also been described using next-generation approaches, permitting the quantification of transcript abundance (mRNA, miRNA, and so forth) and the identification of novel genes and isoforms in an unbiased manner.^{110,113,114,122,169,172} In contrast to the array-based technologies used in gene expression analyses, RNA-Seq requires no a priori knowledge of the transcriptome under investigation—thus enabling full-transcriptome characterization—and eliminates biases associated with array content. Similarly, unbiased NGS has been extended to studies of the mammalian epigenome, including genome-wide analyses of DNA methylomes,^{37,102} mapping of histone modifications,^{9,108} and detailing of the locations of DNA-binding proteins.^{74,139}

Collectively, these emerging NGS-based approaches for studying the cancer genome hold great promise for comprehensive analyses of medulloblastoma. As the cost and bioinformatics involved in next-generation become more mainstream, next-generation-based profiling of the medulloblastoma genome, transcriptome, and epigenome will surely be the priority of several investigative groups (Fig. 6). Undoubtedly, these efforts will lead to a more complete understanding of the genes and pathways involved in the initiation, maintenance, and progression of medulloblastoma. Moreover, as larger patient cohorts are gathered and profiled using these advanced methods, more specific and reliable molecular classification of medulloblastoma will probably be possible. Finally, the correlation of genomic data with patient clinical data,

Genomics of medulloblastoma

such as the presence of metastatic disease and overall survival, will undoubtedly be improved.

Conclusions

Twenty years of studying the medulloblastoma genome has facilitated a detailed description of the medulloblastoma karyotype, led to the identification and validation of bona fide oncogenes and tumor suppressors, and implicated key signaling pathways and networks that are recurrently deregulated. Much of the recent progress in this field is owed to improvements in the technologies available for analyzing the genome. To comprehensively appreciate a cancer genome such as medulloblastoma, unbiased, high-resolution, genome-wide investigations must be undertaken, ideally using a combination of complementary (microarrays and NGS) and integrative (genome, transcriptome, and epigenome) technologies. Of course, an adequate sample size is critical to such studies if a full range of both common and rare genomic changes is to be captured. Large, coordinated multiinstitutional consortiums such as The Cancer Genome Atlas (TCGA) are now applying this philosophy to study the genomes of brain (glioblastoma multiforme), lung (squamous carcinoma), and ovarian (serous cystadenocarcinoma) cancers.²⁶ As part of their pilot project, TCGA is profiling large numbers of tumors of these origins to assess aberrations in DNA sequence (substitutions and indels), genomic copy number (amplifications and deletions), chromosomal composition (rearrangements), DNA methylation (hyper- and hypo-promoter methylation), and gene expression (aberrant expression and splicing). Results from TCGA and other similar large-scale collaborative efforts utilizing this type of broad approach to cancer genomics have recently demonstrated success.^{26,36,78,125} To make progress in the fine genomic mapping of medulloblastoma, analogous strategies are warranted.

The generation of large genomic data sets of medulloblastoma using multiple orthogonal technologies will have its challenges. A logistical issue facing potential large-scale genomic projects on medulloblastoma relates to the immensity of the bioinformatics involved, as profiling large sample cohorts inevitably produces large amounts of data of varying complexity. The integration of multiple genomic data sets for maximal extraction of biological information will be a major priority if these new technologies are to be used to their full potential. In addition, the use of NGS technology for cancer genomics studies is still in its infancy, and the cost as well as the bioinformatics and computing challenges related to this promising technology remain a significant hurdle. Before NGS can be efficiently applied to large-scale medulloblastoma projects, financial feasibility and informatics considerations must be addressed.

Discriminating between so-called driver and passenger mutations is also a common yet critical dilemma in cancer genomics studies.^{124,149} In other words, not all somatic alterations in a cancer genome actually contribute to cancer development and confer a clonal advantage to a tumor cell. Distinguishing genes that provide a clonal advantage (drivers) in tumorigenesis from those that

do not (passengers) requires the integration of multiple data types (copy number, sequencing, and expression) and, ideally, functional validation—neither of which is a simple task when considering possibly hundreds of candidate cancer genes. Thus, the use of genomic studies alone will be insufficient for determining the genes “driving” medulloblastomas, and follow-up functional studies, including mouse models, will be a necessity.

A third issue to consider is the reality of intratumoral heterogeneity and how global profiling strategies are typically performed using nucleic acid extracted from bulk tumor tissue. Methods such as array-based copy number and gene expression profiling essentially produce an average for a genomic region or gene in a given template. Since medulloblastomas are neither histologically nor molecularly monoclonal, genomic events that are present in only a small percentage of cells will be under-called or missed outright when bulk tumor is the source of the template queried. Indeed, the amplification of known medulloblastoma oncogenes, such as *MYC* and *MYCN*, is often found in only 10–20% of cells as determined by FISH (S. Pfister, personal communication, 2009), suggesting that these events are under-called by array profiling. Strategies that involve the analysis of distinct cell populations (that is, laser capture microdissection and cell sorting) or even single cells within a tumor will be required to avoid losing potentially valuable genetic information present only in tumor cell subpopulations.

Despite these relevant technical and logistical considerations, the next few years promise to be an exciting period for the community studying medulloblastoma. Large-scale, collaborative genomics projects will provide a more detailed characterization of this genome than ever before, and, optimistically, many new candidates will be uncovered. These efforts should continue to improve our ability to diagnose, stratify, and treat medulloblastoma, eventually leading to decreased deaths and improved quality of life for patients.

Disclosure

The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.

Acknowledgments

The authors sincerely thank Paul Paroutis and Christian Smith for assistance with artwork and figure preparation.

References

1. Adesina AM, Nguyen Y, Mehta V, Takei H, Stangeby P, Crabtree S, et al: FOXG1 dysregulation is a frequent event in medulloblastoma. *J Neurooncol* **85**:111–122, 2007
2. Aldosari N, Wiltshire RN, Dutra A, Schrock E, McLendon RE, Friedman HS, et al: Comprehensive molecular cytogenetic investigation of chromosomal abnormalities in human medulloblastoma cell lines and xenograft. *Neuro Oncol* **4**:75–85, 2002
3. Ambros V: The functions of animal microRNAs. *Nature* **431**:350–355, 2004
4. Anderton JA, Lindsey JC, Lusher ME, Gilbertson RJ, Bailey S, Ellison DW, et al: Global analysis of the medulloblastoma

- epigenome identifies disease-subgroup-specific inactivation of COL1A2. **Neuro Oncol** 10:981–994, 2008
5. Ansorge WJ: Next-generation DNA sequencing techniques. **N Biotechnol** 25:195–203, 2009
6. Attard TM, Giglio P, Koppula S, Snyder C, Lynch HT: Brain tumors in individuals with familial adenomatous polyposis: a cancer registry experience and pooled case report analysis. **Cancer** 109:761–766, 2007
7. Avet-Loiseau H, Vénat AM, Terrier-Lacombe MJ, Lellouch-Tubiana A, Zerah M, Vassal G: Comparative genomic hybridization detects many recurrent imbalances in central nervous system primitive neuroectodermal tumours in children. **Br J Cancer** 79:1843–1847, 1999
8. Badiali M, Pession A, Basso G, Andreini L, Rigobello L, Galassi E, et al: N-myc and c-myc oncogenes amplification in medulloblastomas. Evidence of particularly aggressive behavior of a tumor with c-myc amplification. **Tumori** 77:118–121, 1991
9. Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z, et al: High-resolution profiling of histone methylations in the human genome. **Cell** 129:823–837, 2007
10. Bartel DP: MicroRNAs: target recognition and regulatory functions. **Cell** 136:215–233, 2009
11. Bayani J, Squire JA: Traditional banding of chromosomes for cytogenetic analysis. **Curr Protoc Cell Biol Chapter 22**:Unit 22.3, 2004
12. Bayani J, Zielenska M, Marrano P, Kwan Ng Y, Taylor MD, Jay V, et al: Molecular cytogenetic analysis of medulloblastomas and supratentorial primitive neuroectodermal tumors by using conventional banding, comparative genomic hybridization, and spectral karyotyping. **J Neurosurg** 93:437–448, 2000
13. Bayani JM, Squire JA: Applications of SKY in cancer cytogenetics. **Cancer Invest** 20:373–386, 2002
14. Behesti H, Marino S: Cerebellar granule cells: insights into proliferation, differentiation, and role in medulloblastoma pathogenesis. **Int J Biochem Cell Biol** 41:435–445, 2009
15. Bentley DR, Balasubramanian S, Swerdlow HP, Smith GP, Milton J, Brown CG, et al: Accurate whole human genome sequencing using reversible terminator chemistry. **Nature** 456:53–59, 2008
16. Bernstein BE, Meissner A, Lander ES: The mammalian epigenome. **Cell** 128:669–681, 2007
17. Biegel JA, Rorke LB, Packer RJ, Sutton LN, Schut L, Bonner K, et al: Isochromosome 17q in primitive neuroectodermal tumors of the central nervous system. **Genes Chromosomes Cancer** 1:139–147, 1989
18. Bigner SH, Friedman HS, Vogelstein B, Oakes WJ, Bigner DD: Amplification of the c-myc gene in human medulloblastoma cell lines and xenografts. **Cancer Res** 50:2347–2350, 1990
19. Bigner SH, Mark J, Friedman HS, Biegel JA, Bigner DD: Structural chromosomal abnormalities in human medulloblastoma. **Cancer Genet Cytogenet** 30:91–101, 1988
20. Bigner SH, McLendon RE, Fuchs H, McKeever PE, Friedman HS: Chromosomal characteristics of childhood brain tumors. **Cancer Genet Cytogenet** 97:125–134, 1997
21. Boon K, Eberhart CG, Riggins GJ: Genomic amplification of orthodenticle homologue 2 in medulloblastomas. **Cancer Res** 65:703–707, 2005
22. Boon K, Edwards JB, Siu IM, Olschner D, Eberhart CG, Marra MA, et al: Comparison of medulloblastoma and normal neural transcriptomes identifies a restricted set of activated genes. **Oncogene** 22:7687–7694, 2003
23. Brena RM, Costello JF: Genome-epigenome interactions in cancer. **Hum Mol Genet** 16 (Spec No 1):R96–R105, 2007
24. Calin GA, Croce CM: MicroRNA signatures in human cancers. **Nat Rev Cancer** 6:857–866, 2006
25. Campbell PJ, Stephens PJ, Pleasance ED, O'Meara S, Li H, Santarius T, et al: Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. **Nat Genet** 40:722–729, 2008
26. Cancer Genome Atlas Research Network: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. **Nature** 455:1061–1068, 2008
27. Chiang DY, Getz G, Jaffe DB, O'Kelly MJ, Zhao X, Carter SL, et al: High-resolution mapping of copy-number alterations with massively parallel sequencing. **Nat Methods** 6:99–103, 2009
28. Clifford SC, Lusher ME, Lindsey JC, Langdon JA, Gilbertson RJ, Straughton D, et al: Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular subgroup of medulloblastomas associated with a favorable prognosis. **Cell Cycle** 5:2666–2670, 2006
29. Cogen PH, Daneshvar L, Metzger AK, Duyk G, Edwards MS, Sheffield VC: Involvement of multiple chromosome 17p loci in medulloblastoma tumorigenesis. **Am J Hum Genet** 50:584–589, 1992
30. Cogen PH, Daneshvar L, Metzger AK, Edwards MS: Deletion mapping of the medulloblastoma locus on chromosome 17p. **Genomics** 8:279–285, 1990
31. Cohen BH, Zeltzer PM, Boyett JM, Geyer JR, Allen JC, Finlay JL, et al: Prognostic factors and treatment results for supratentorial primitive neuroectodermal tumors in children using radiation and chemotherapy: a Childrens Cancer Group randomized trial. **J Clin Oncol** 13:1687–1696, 1995
32. Cohen N, Betts DR, Tavori U, Toren A, Ram T, Constantini S, et al: Karyotypic evolution pathways in medulloblastoma/primitive neuroectodermal tumor determined with a combination of spectral karyotyping, G-banding, and fluorescence in situ hybridization. **Cancer Genet Cytogenet** 149:44–52, 2004
33. Coombs A: The sequencing shakeup. **Nat Biotechnol** 26:1109–1112, 2008
34. Davies JJ, Wilson IM, Lam WL: Array CGH technologies and their applications to cancer genomes. **Chromosome Res** 13:237–248, 2005
35. Di C, Liao S, Adamson DC, Parrett TJ, Broderick DK, Shi Q, et al: Identification of OTX2 as a medulloblastoma oncogene whose product can be targeted by all-trans retinoic acid. **Cancer Res** 65:919–924, 2005
36. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, et al: Somatic mutations affect key pathways in lung adenocarcinoma. **Nature** 455:1069–1075, 2008
37. Down TA, Rakyen VK, Turner DJ, Flicek P, Li H, Kulesha E, et al: A Bayesian deconvolution strategy for immunoprecipitation-based DNA methylome analysis. **Nat Biotechnol** 26:779–785, 2008
38. Eberhart CG, Kratz JE, Schuster A, Goldthwaite P, Cohen KJ, Perlman EJ, et al: Comparative genomic hybridization detects an increased number of chromosomal alterations in large cell/anaplastic medulloblastomas. **Brain Pathol** 12:36–44, 2002
39. Ehrbrecht A, Müller U, Wolter M, Hoischen A, Koch A, Radlwimmer B, et al: Comprehensive genomic analysis of desmoplastic medulloblastomas: identification of novel amplified genes and separate evaluation of the different histological components. **J Pathol** 208:554–563, 2006
40. Ellison DW, Clifford SC, Gajjar A, Gilbertson RJ: What's new in neuro-oncology? Recent advances in medulloblastoma. **Eur J Paediatr Neurol** 7:53–66, 2003
41. Esquela-Kerscher A, Slack FJ: Oncomirs—microRNAs with a role in cancer. **Nat Rev Cancer** 6:259–269, 2006
42. Esteller M: Epigenetics in cancer. **N Engl J Med** 358:1148–1159, 2008
43. Fattet S, Haberler C, Legoix P, Varlet P, Lellouch-Tubiana A, Lair S, et al: Beta-catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics. **J Pathol** 218:86–94, 2009

44. Ferretti E, De Smaele E, Miele E, Laneve P, Po A, Pelloni M, et al: Concerted microRNA control of Hedgehog signalling in cerebellar neuronal progenitor and tumour cells. **EMBO J** **27**:2616–2627, 2008
45. Ferretti E, De Smaele E, Po A, Di Marcotullio L, Tosi E, Espinola MS, et al: MicroRNA profiling in human medulloblastoma. **Int J Cancer** **124**:568–577, 2009
46. Finlay JL, Erdreich-Epstein A, Packer RJ: Progress in the treatment of childhood brain tumors: no room for complacency. **Pediatr Hematol Oncol** **24**:79–84, 2007
47. Fogarty MP, Kessler JD, Wechsler-Reya RJ: Morphing into cancer: the role of developmental signaling pathways in brain tumor formation. **J Neurobiol** **64**:458–475, 2005
48. Friedman HS, Burger PC, Bigner SH, Trojanowski JQ, Brodeur GM, He XM, et al: Phenotypic and genotypic analysis of a human medulloblastoma cell line and transplantable xenograft (D341 Med) demonstrating amplification of c-myc. **Am J Pathol** **130**:472–484, 1988
49. Frühwald MC, O'Dorisio MS, Dai Z, Tanner SM, Balster DA, Gao X, et al: Aberrant promoter methylation of previously unidentified target genes is a common abnormality in medulloblastomas—implications for tumor biology and potential clinical utility. **Oncogene** **20**:5033–5042, 2001
50. Fults DW: Modeling medulloblastoma with genetically engineered mice. **Neurosurg Focus** **19**(5):E7, 2005
51. Gailani MR, Bale SJ, Leffell DJ, DiGiovanna JJ, Peck GL, Poliak S, et al: Developmental defects in Gorlin syndrome related to a putative tumor suppressor gene on chromosome 9. **Cell** **69**:111–117, 1992
52. Gajjar A, Chintagumpala M, Ashley D, Kellie S, Kun LE, Merchant TE, et al: Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. **Lancet Oncol** **7**:813–820, 2006
53. Gajjar A, Hernan R, Kocak M, Fuller C, Lee Y, McKinnon PJ, et al: Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma. **J Clin Oncol** **22**:984–993, 2004
54. Gilbertson RJ, Clifford SC: PDGFRB is overexpressed in metastatic medulloblastoma. **Nat Genet** **35**:197–198, 2003
55. Gilbertson RJ, Ellison DW: The origins of medulloblastoma subtypes. **Annu Rev Pathol** **3**:341–365, 2008
56. Gilhuis HJ, Anderl KL, Boerman RH, Jeuken JM, James CD, Raffel C, et al: Comparative genomic hybridization of medulloblastomas and clinical relevance: eleven new cases and a review of the literature. **Clin Neurol Neurosurg** **102**:203–209, 2000
57. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, et al: Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. **Science** **286**:531–537, 1999
58. Gonzalez-Gomez P, Bello MJ, Inda MM, Alonso ME, Arjona D, Amínoso C, et al: Deletion and aberrant CpG island methylation of Caspase 8 gene in medulloblastoma. **Oncol Rep** **12**:663–666, 2004
59. Griffin CA, Hawkins AL, Packer RJ, Rorke LB, Emanuel BS: Chromosome abnormalities in pediatric brain tumors. **Cancer Res** **48**:175–180, 1988
60. Grimmer MR, Weiss WA: Childhood tumors of the nervous system as disorders of normal development. **Curr Opin Pediatr** **18**:634–638, 2006
61. Grotzer MA, Eggert A, Zuzak TJ, Janss AJ, Marwaha S, Wiewrodt BR, et al: Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression. **Oncogene** **19**:4604–4610, 2000
62. Hahn H, Wicking C, Zaphiropoulos PG, Gailani MR, Shanley S, Chidambaram A, et al: Mutations of the human homolog of *Drosophila patched* in the nevoid basal cell carcinoma syndrome. **Cell** **85**:841–851, 1996
63. Hamilton SR, Liu B, Parsons RE, Papadopoulos N, Jen J, Powell SM, et al: The molecular basis of Turcot's syndrome. **N Engl J Med** **332**:839–847, 1995
64. Hammond SM: MicroRNAs as oncogenes. **Curr Opin Genet Dev** **16**:4–9, 2006
65. Harada K, Toyooka S, Maitra A, Maruyama R, Toyooka KO, Timmons CF, et al: Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines. **Oncogene** **21**:4345–4349, 2002
66. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, et al: A microRNA polycistron as a potential human oncogene. **Nature** **435**:828–833, 2005
67. Hodges E, Xuan Z, Balija V, Kramer M, Molla MN, Smith SW, et al: Genome-wide in situ exon capture for selective resequencing. **Nat Genet** **39**:1522–1527, 2007
68. Horiguchi K, Tomizawa Y, Tosaka M, Ishiuchi S, Kurihara H, Mori M, et al: Epigenetic inactivation of RASSF1A candidate tumor suppressor gene at 3p21.3 in brain tumors. **Oncogene** **22**:7862–7865, 2003
69. Huang J, Wei W, Zhang J, Liu G, Bignell GR, Stratton MR, et al: Whole genome DNA copy number changes identified by high density oligonucleotide arrays. **Hum Genomics** **1**:287–299, 2004
70. Hui AB, Takano H, Lo KW, Kuo WL, Lam CN, Tong CY, et al: Identification of a novel homozygous deletion region at 6q23.1 in medulloblastomas using high-resolution array comparative genomic hybridization analysis. **Clin Cancer Res** **11**:4707–4716, 2005
71. International Human Genome Sequencing Consortium: Finishing the euchromatic sequence of the human genome. **Nature** **431**:931–945, 2004
72. James CD, He J, Carlsson E, Mikkelsen T, Ridderheim PA, Cavenee WK, et al: Loss of genetic information in central nervous system tumors common to children and young adults. **Genes Chromosomes Cancer** **2**:94–102, 1990
73. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al: Cancer statistics, 2008. **CA Cancer J Clin** **58**:71–96, 2008
74. Johnson DS, Mortazavi A, Myers RM, Wold B: Genome-wide mapping of in vivo protein-DNA interactions. **Science** **316**:1497–1502, 2007
75. Jones PA, Baylin SB: The epigenomics of cancer. **Cell** **128**:683–692, 2007
76. Jones PA, Baylin SB: The fundamental role of epigenetic events in cancer. **Nat Rev Genet** **3**:415–428, 2002
77. Jones S, Hruban RH, Kamiyama M, Borges M, Zhang X, Parsons DW, et al: Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. **Science** **324**:217, 2009
78. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, et al: Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. **Science** **321**:1801–1806, 2008
79. Kasuga C, Nakahara Y, Ueda S, Hawkins C, Taylor MD, Smith CA, et al: Expression of MAGE and GAGE genes in medulloblastoma and modulation of resistance to chemotherapy. Laboratory investigation. **J Neurosurg Pediatr** **1**:305–313, 2008
80. Kim JI, Ju YS, Park H, Kim S, Lee S, Yi JH, et al: A highly annotated whole-genome sequence of a Korean individual. **Nature** **460**:1011–1015, 2009
81. Kongkham PN, Northcott PA, Ra YS, Nakahara Y, Mainprize TG, Croul SE, et al: An epigenetic genome-wide screen identifies SPINT2 as a novel tumor suppressor gene in pediatric medulloblastoma. **Cancer Res** **68**:9945–9953, 2008
82. Kool M, Koster J, Bunt J, Hasselt NE, Lakeman A, van Sluis P, et al: Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. **PLoS One** **3**:e3088, 2008
83. Kortmann RD, Kühl J, Timmermann B, Mittler U, Urban C,

- Budach V, et al: Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT '91. **Int J Radiat Oncol Biol Phys** **46**:269–279, 2000
84. Kouzarides T: Chromatin modifications and their function. **Cell** **128**:693–705, 2007
85. LaFramboise T: Single nucleotide polymorphism arrays: a decade of biological, computational and technological advances. **Nucleic Acids Res** **37**:4181–4193, 2009
86. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al: Initial sequencing and analysis of the human genome. **Nature** **409**:860–921, 2001
87. Leary RJ, Cummins J, Wang TL, Velculescu VE: Digital karyotyping. **Nat Protoc** **2**:1973–1986, 2007
88. Ley TJ, Mardis ER, Ding L, Fulton B, McLellan MD, Chen K, et al: DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. **Nature** **456**:66–72, 2008
89. Li MH, Bouffett E, Hawkins CE, Squire JA, Huang A: Molecular genetics of supratentorial primitive neuroectodermal tumors and pineoblastoma. **Neurosurg Focus** **19**(5):E3, 2005
90. Lindsey JC, Anderton JA, Lusher ME, Clifford SC: Epigenetic events in medulloblastoma development. **Neurosurg Focus** **19**(5):E10, 2005
91. Lindsey JC, Lusher ME, Anderton JA, Bailey S, Gilbertson RJ, Pearson AD, et al: Identification of tumour-specific epigenetic events in medulloblastoma development by hypermethylation profiling. **Carcinogenesis** **25**:661–668, 2004
92. Lo KC, Rossi MR, Eberhart CG, Cowell JK: Genome wide copy number abnormalities in pediatric medulloblastomas as assessed by array comparative genome hybridization. **Brain Pathol** **17**:282–296, 2007
93. Lusher ME, Lindsey JC, Latif F, Pearson AD, Ellison DW, Clifford SC: Biallelic epigenetic inactivation of the RASSF1A tumor suppressor gene in medulloblastoma development. **Cancer Res** **62**:5906–5911, 2002
94. MacDonald TJ, Brown KM, LaFleur B, Peterson K, Lawlor C, Chen Y, et al: Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. **Nat Genet** **29**:143–152, 2001
95. Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, et al: Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. **Science** **250**:1233–1238, 1990
96. Marino S: Medulloblastoma: developmental mechanisms out of control. **Trends Mol Med** **11**:17–22, 2005
97. Marrett LD, De P, Airia P, Dryer D: Cancer in Canada in 2008. **CMAJ** **179**:1163–1170, 2008
98. Matsuzaki H, Dong S, Loi H, Di X, Liu G, Hubbell E, et al: Genotyping over 100,000 SNPs on a pair of oligonucleotide arrays. **Nat Methods** **1**:109–111, 2004
99. Matsuzaki H, Loi H, Dong S, Tsai YY, Fang J, Law J, et al: Parallel genotyping of over 10,000 SNPs using a one-primer assay on a high-density oligonucleotide array. **Genome Res** **14**:414–425, 2004
100. McCabe MG, Ichimura K, Liu L, Plant K, Bäcklund LM, Pearson DM, et al: High-resolution array-based comparative genomic hybridization of medulloblastomas and supratentorial primitive neuroectodermal tumors. **J Neuropathol Exp Neurol** **65**:549–561, 2006
101. McNeil DE, Coté TR, Clegg L, Rorke LB: Incidence and trends in pediatric malignancies medulloblastoma/primitive neuroectodermal tumor: a SEER update. **Surveillance Epidemiology and End Results. Med Pediatr Oncol** **39**:190–194, 2002
102. Meissner A, Mikkelsen TS, Gu H, Wernig M, Hanna J, Sivachenko A, et al: Genome-scale DNA methylation maps of pluripotent and differentiated cells. **Nature** **454**:766–770, 2008
103. Mendell JT: miRiad roles for the miR-17-92 cluster in development and disease. **Cell** **133**:217–222, 2008
104. Mendrzyk F, Radlwimmer B, Joos S, Kokocinski F, Benner A, Stange DE, et al: Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma. **J Clin Oncol** **23**:8853–8862, 2005
105. Mertens F, Johansson B, Mitelman F: Isochromosomes in neoplasia. **Genes Chromosomes Cancer** **10**:221–230, 1994
106. Metzker ML: Emerging technologies in DNA sequencing. **Genome Res** **15**:1767–1776, 2005
107. Michiels EM, Oussoren E, Van Groenigen M, Pauws E, Bossuyt PM, Voûte PA, et al: Genes differentially expressed in medulloblastoma and fetal brain. **Physiol Genomics** **1**:83–91, 1999
108. Mikkelsen TS, Ku M, Jaffe DB, Issac B, Lieberman E, Gnannoukos G, et al: Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. **Nature** **448**:553–560, 2007
109. Mischel PS, Cloughesy TF, Nelson SF: DNA-microarray analysis of brain cancer: molecular classification for therapy. **Nat Rev Neurosci** **5**:782–792, 2004
110. Morin RD, O'Connor MD, Griffith M, Kuchenbauer F, Delaney A, Prabhu AL, et al: Application of massively parallel sequencing to microRNA profiling and discovery in human embryonic stem cells. **Genome Res** **18**:610–621, 2008
111. Morozova O, Marra MA: Applications of next-generation sequencing technologies in functional genomics. **Genomics** **92**:255–264, 2008
112. Morozova O, Marra MA: From cytogenetics to next-generation sequencing technologies: advances in the detection of genome rearrangements in tumors. **Biochem Cell Biol** **86**:81–91, 2008
113. Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B: Mapping and quantifying mammalian transcriptomes by RNA-Seq. **Nat Methods** **5**:621–628, 2008
114. Nagalakshmi U, Wang Z, Waern K, Shou C, Raha D, Gerstein M, et al: The transcriptional landscape of the yeast genome defined by RNA sequencing. **Science** **320**:1344–1349, 2008
115. Neben K, Korshunov A, Benner A, Wrobel G, Hahn M, Kokocinski F, et al: Microarray-based screening for molecular markers in medulloblastoma revealed STK15 as independent predictor for survival. **Cancer Res** **64**:3103–3111, 2004
116. Ng SB, Turner EH, Robertson PD, Flygare SD, Bigham AW, Lee C, et al: Targeted capture and massively parallel sequencing of 12 human exomes. **Nature** **461**:272–276, 2009
117. Nicholson J, Wickramasinghe C, Ross F, Crolla J, Ellison D: Imbalances of chromosome 17 in medulloblastomas determined by comparative genomic hybridisation and fluorescence in situ hybridisation. **Mol Pathol** **53**:313–319, 2000
118. Northcott PA, Fernandez-L A, Hagan JP, Ellison DW, Grajkowska W, Gillespie Y, et al: The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors. **Cancer Res** **69**:3249–3255, 2009
119. Northcott PA, Nakahara Y, Wu X, Feuk L, Ellison DW, Croul S, et al: Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma. **Nat Genet** **41**:465–472, 2009
120. Nutt CL, Mani DR, Betensky RA, Tamayo P, Cairncross JG, Ladd C, et al: Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. **Cancer Res** **63**:1602–1607, 2003
121. Ogawa H, Ishiguro K, Gaubatz S, Livingston DM, Nakatani Y: A complex with chromatin modifiers that occupies E2F- and Myc-responsive genes in G0 cells. **Science** **296**:1132–1136, 2002
122. Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ: Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. **Nat Genet** **40**:1413–1415, 2008
123. Park PC, Taylor MD, Mainprize TG, Becker LE, Ho M, Dura WT, et al: Transcriptional profiling of medulloblastoma in children. **J Neurosurg** **99**:534–541, 2003

124. Parmigiani G, Boca S, Lin J, Kinzler KW, Velculescu V, Vogelstein B: Design and analysis issues in genome-wide somatic mutation studies of cancer. **Genomics** **93**:17–21, 2009
125. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al: An integrated genomic analysis of human glioblastoma multiforme. **Science** **321**:1807–1812, 2008
126. Pfister S, Remke M, Benner A, Mendrzyk F, Toedt G, Felsberg J, et al: Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. **J Clin Oncol** **27**:1627–1636, 2009
127. Pfister S, Remke M, Toedt G, Werft W, Benner A, Mendrzyk F, et al: Supratentorial primitive neuroectodermal tumors of the central nervous system frequently harbor deletions of the CDKN2A locus and other genomic aberrations distinct from medulloblastomas. **Genes Chromosomes Cancer** **46**:839–851, 2007
128. Pfister S, Schlaeger C, Mendrzyk F, Wittmann A, Benner A, Kulozik A, et al: Array-based profiling of reference-independent methylation status (aPRIMES) identifies frequent promoter methylation and consecutive downregulation of ZIC2 in pediatric medulloblastoma. **Nucleic Acids Res** **35**:e51, 2007
129. Piedimonte LR, Wailes IK, Weiner HL: Medulloblastoma: mouse models and novel targeted therapies based on the Sonic hedgehog pathway. **Neurosurg Focus** **19**(5):E8, 2005
130. Pietsch T, Scharmann T, Fonatsch C, Schmidt D, Ockler R, Freihoff D, et al: Characterization of five new cell lines derived from human primitive neuroectodermal tumors of the central nervous system. **Cancer Res** **54**:3278–3287, 1994
131. Polyak K, Riggins GJ: Gene discovery using the serial analysis of gene expression technique: implications for cancer research. **J Clin Oncol** **19**:2948–2958, 2001
132. Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla LM, Angelo M, McLaughlin ME, et al: Prediction of central nervous system embryonal tumour outcome based on gene expression. **Nature** **415**:436–442, 2002
133. Pruitt KD, Tatusova T, Maglott DR: NCBI reference sequences (RefSeq): a curated non-redundant sequence database of genomes, transcripts and proteins. **Nucleic Acids Res** **35** (Database issue):D61–D65, 2007
134. Raffel C: Medulloblastoma: molecular genetics and animal models. **Neoplasia** **6**:310–322, 2004
135. Raffel C, Gilles FE, Weinberg KI: Reduction to homozygosity and gene amplification in central nervous system primitive neuroectodermal tumors of childhood. **Cancer Res** **50**:587–591, 1990
136. Reardon DA, Michalkiewicz E, Boyett JM, Sublett JE, Entreklin RE, Ragsdale ST, et al: Extensive genomic abnormalities in childhood medulloblastoma by comparative genomic hybridization. **Cancer Res** **57**:4042–4047, 1997
137. Reddy AT, Janss AJ, Phillips PC, Weiss HL, Packer RJ: Outcome for children with supratentorial primitive neuroectodermal tumors treated with surgery, radiation, and chemotherapy. **Cancer** **88**:2189–2193, 2000
138. Rickert CH, Paulus W: Comparative genomic hybridization in central and peripheral nervous system tumors of childhood and adolescence. **J Neuropathol Exp Neurol** **63**:399–417, 2004
139. Robertson G, Hirst M, Bainbridge M, Bilenky M, Zhao Y, Zeng T, et al: Genome-wide profiles of STAT1 DNA association using chromatin immunoprecipitation and massively parallel sequencing. **Nat Methods** **4**:651–657, 2007
140. Rood BR, Zhang H, Weitman DM, Cogen PH: Hypermethylation of HIC-1 and 17p allelic loss in medulloblastoma. **Cancer Res** **62**:3794–3797, 2002
141. Rorke LB: Classification and grading of childhood brain tumors. Overview and statement of the problem. **Cancer** **56** (7 Suppl):1848–1849, 1985
142. Rossi MR, Conroy J, McQuaid D, Nowak NJ, Rutka JT, Cowell JK: Array CGH analysis of pediatric medulloblastomas. **Genes Chromosomes Cancer** **45**:290–303, 2006
143. Rusk N, Kiermer V: Primer: Sequencing—the next generation. **Nat Methods** **5**:15, 2008
144. Saha S, Sparks AB, Rago C, Akmaev V, Wang CJ, Vogelstein B, et al: Using the transcriptome to annotate the genome. **Nat Biotechnol** **20**:508–512, 2002
145. Schuster SC: Next-generation sequencing transforms today's biology. **Nat Methods** **5**:16–18, 2008
146. Shendure J, Ji H: Next-generation DNA sequencing. **Nat Biotechnol** **26**:1135–1145, 2008
147. Speicher MR, Carter NP: The new cytogenetics: blurring the boundaries with molecular biology. **Nat Rev Genet** **6**:782–792, 2005
148. Srivastava S, Zou ZQ, Pirolo K, Blattner W, Chang EH: Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. **Nature** **348**:747–749, 1990
149. Stratton MR, Campbell PJ, Futreal PA: The cancer genome. **Nature** **458**:719–724, 2009
150. Tachibana M, Ueda J, Fukuda M, Takeda N, Ohta T, Iwanari H, et al: Histone methyltransferases G9a and GLP form heteromeric complexes and are both crucial for methylation of euchromatin at H3-K9. **Genes Dev** **19**:815–826, 2005
151. Taylor MD, Mainprize TG, Rutka JT: Molecular insight into medulloblastoma and central nervous system primitive neuroectodermal tumor biology from hereditary syndromes: a review. **Neurosurgery** **47**:888–901, 2000
152. Taylor RE, Bailey CC, Robinson KJ, Weston CL, Walker DA, Ellison D, et al: Outcome for patients with metastatic (M2-3) medulloblastoma treated with SIOP/UKCCSG PNET-3 chemotherapy. **Eur J Cancer** **41**:727–734, 2005
153. Thomas GA, Raffel C: Loss of heterozygosity on 6q, 16q, and 17p in human central nervous system primitive neuroectodermal tumors. **Cancer Res** **51**:639–643, 1991
154. Thompson MC, Fuller C, Hogg TL, Dalton J, Finkelstein D, Lau CC, et al: Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. **J Clin Oncol** **24**:1924–1931, 2006
155. Timmermann B, Kortmann RD, Kühl J, Meisner C, Dieckmann K, Pietsch T, et al: Role of radiotherapy in the treatment of supratentorial primitive neuroectodermal tumors in childhood: results of the prospective German brain tumor trials HIT 88/89 and 91. **J Clin Oncol** **20**:842–849, 2002
156. Ting AH, McGarvey KM, Baylin SB: The cancer epigenome—components and functional correlates. **Genes Dev** **20**:3215–3231, 2006
157. Tomlinson FH, Jenkins RB, Scheithauer BW, Keelan PA, Ritland S, Parisi JE, et al: Aggressive medulloblastoma with high-level N-myc amplification. **Mayo Clin Proc** **69**:359–365, 1994
158. Uziel T, Karginov FV, Xie S, Parker JS, Wang YD, Gajjar A, et al: The miR-17-92 cluster collaborates with the Sonic Hedgehog pathway in medulloblastoma. **Proc Natl Acad Sci U S A** **106**:2812–2817, 2009
159. van Ruisen F, Baas F: Serial analysis of gene expression (SAGE). **Methods Mol Biol** **383**:41–66, 2007
160. Velculescu VE: Essay: Amersham Pharmacia Biotech & Science prize. Tantalizing transcriptomes—SAGE and its use in global gene expression analysis. **Science** **286**:1491–1492, 1999
161. Velculescu VE, Zhang L, Vogelstein B, Kinzler KW: Serial analysis of gene expression. **Science** **270**:484–487, 1995
162. Velculescu VE, Zhang L, Zhou W, Vogelstein J, Basrai MA, Bassett DE Jr, et al: Characterization of the yeast transcriptome. **Cell** **88**:243–251, 1997
163. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, et al: The sequence of the human genome. **Science** **291**:1304–1351, 2001
164. von Stein OD: Isolation of differentially expressed genes through subtractive suppression hybridization. **Methods Mol Biol** **175**:263–278, 2001
165. Waha A, Koch A, Hartmann W, Milde U, Felsberg J, Hübner A, et al: SGNE1/7B2 is epigenetically altered and transcription-

- ally downregulated in human medulloblastomas. **Oncogene** **26**:5662–5668, 2007
166. Waha A, Waha A, Koch A, Meyer-Puttlitz B, Weggen S, Sørensen N, et al: Epigenetic silencing of the HIC-1 gene in human medulloblastomas. **J Neuropathol Exp Neurol** **62**:1192–1201, 2003
167. Wang J, Wang W, Li R, Li Y, Tian G, Goodman L, et al: The diploid genome sequence of an Asian individual. **Nature** **456**:60–65, 2008
168. Wang TL, Maierhofer C, Speicher MR, Lengauer C, Vogelstein B, Kinzler KW, et al: Digital karyotyping. **Proc Natl Acad Sci U S A** **99**:16156–16161, 2002
169. Wang Z, Gerstein M, Snyder M: RNA-Seq: a revolutionary tool for transcriptomics. **Nat Rev Genet** **10**:57–63, 2009
170. Wechsler-Reya R, Scott MP: The developmental biology of brain tumors. **Annu Rev Neurosci** **24**:385–428, 2001
171. Wheeler DA, Srinivasan M, Egholm M, Shen Y, Chen L, McGuire A, et al: The complete genome of an individual by massively parallel DNA sequencing. **Nature** **452**:872–876, 2008
172. Wilhelm BT, Marguerat S, Watt S, Schubert F, Wood V, Goodhead I, et al: Dynamic repertoire of a eukaryotic transcriptome surveyed at single-nucleotide resolution. **Nature** **453**:1239–1243, 2008
173. Wood LD, Parsons DW, Jones S, Lin J, Sjöblom T, Leary RJ, et al: The genomic landscapes of human breast and colorectal cancers. **Science** **318**:1108–1113, 2007
174. Yan PS, Potter D, Deatherage DE, Huang TH, Lin S: Differential methylation hybridization: profiling DNA methylation with a high-density CpG island microarray. **Methods Mol Biol** **507**:89–106, 2009
175. Yokota N, Mainprize TG, Taylor MD, Kohata T, Loreto M, Ueda S, et al: Identification of differentially expressed and developmentally regulated genes in medulloblastoma using suppression subtraction hybridization. **Oncogene** **23**:3444–3453, 2004
176. Yoshimoto M, Bayani J, Nuin PA, Silva NS, Cavalheiro S, Stavale JN, et al: Metaphase and array comparative genomic hybridization: unique copy number changes and gene amplification of medulloblastomas in South America. **Cancer Genet Cytogenet** **170**:40–47, 2006
177. Zeltzer PM, Boyett JM, Finlay JL, Albright AL, Rorke LB, Milstein JM, et al: Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study. **J Clin Oncol** **17**:832–845, 1999

Manuscript submitted September 18, 2009.

Accepted October 22, 2009.

Address correspondence to: Michael D. Taylor, M.D., Ph.D., Division of Neurosurgery, The Hospital for Sick Children, 555 University Avenue, Suite 1504, Toronto, Ontario, M5G 1X8, Canada. email: mdtaylor@sickkids.ca.